Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

NewAmsterdam Pharma Company N.V. (NAMS) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

NewAmsterdam Pharma Company N.V. (NAMS), most recent 12 months reported: revenue $7.12M, net loss $259.5M, free cash flow -$143.72M. Latest balance sheet on file: liquid cash $633.85M. From SEC filings. Others in Pharmaceutical Preparations: Coya Therapeutics, Inc. · Adagene Inc. · ROIVANT SCIENCES LTD. · Alumis Inc. · HCW Biologics Inc. · RANI THERAPEUTICS HOLDINGS, INC. · Bolt Biotherapeutics, Inc. · ENTRADA THERAPEUTICS, INC.

Stock screener

Watchlist